Haemonetics' Strategic Moves Poised To Boost Margins And Earnings, Says Analyst
Needham upgraded Haemonetics to Buy from Hold with a $112 price target, citing improved margin outlook.
Key factors for margin growth: reduced low-margin Plasma sales and expanded high-margin Interventional Technologies sales.
Trade with 70% Backtested Accuracy
Analyst Views on NBSM
About the author
Toro Lowers Full-Year Outlook As Residential Sales Slump, Costs Weigh on Margins
Sales Performance: The Toro Company reported a 2% decrease in second-quarter fiscal 2025 sales to $1.32 billion, missing expectations, with significant declines in the residential segment and adjusted EPS slightly beating consensus.
FY25 Outlook: The company has lowered its FY25 adjusted EPS guidance and net sales growth outlook, while emphasizing strategic steps to navigate macroeconomic challenges, as reflected in a decline of TTC shares by 1.8%.
ITT Q1 Preliminary Results: Flat Revenue, Eyes $1 Billion In Orders, $500 Million In New Buybacks & More
Company Performance and Outlook: ITT Inc. shares fell premarket as the company reported preliminary first-quarter results, projecting $1.0 billion in orders and over $900 million in revenue, with adjusted EPS expected between $1.43 to $1.45. Revenue growth is anticipated from pumps aftermarket and connectors, despite weak aerospace demand.
Share Repurchase and New Product Launch: ITT plans to repurchase up to an additional $500 million in shares under its existing buyback plan and recently launched VIDAR, a smart motor aimed at reducing energy use and CO2 emissions, marking its entry into the industrial motor market.
Toro's Q1 Sales Miss Expectations, Weighed Down by Material Costs and Promotions
Quarterly Performance: The Toro Company reported a 1% decrease in first-quarter fiscal 2025 sales to $995 million, missing expectations, with residential segment sales down 8% while professional segment sales increased by 1.6%. Adjusted EPS rose 2% year-over-year to $0.65, surpassing estimates.
Future Outlook: Toro expects net sales growth of 0%-1% and adjusted EPS between $4.25 and $4.40 for FY25, amid uncertainties in the macro environment. The company has achieved $64 million in cost savings and aims for $100 million by fiscal 2027, planning to reinvest some savings for innovation and growth.
Why Is Outdoor Equipment Products Provider Toro Stock Plunging Today?
Third-Quarter Performance: The Toro Company reported a 6.9% year-over-year sales increase to $1.156 billion, which fell short of expectations, with adjusted EPS of $1.18 also missing consensus estimates. The company noted increased caution among homeowners and dealers affecting shipments.
FY24 Outlook and Future Initiatives: Toro revised its FY24 net sales growth expectation to about 1% and adjusted EPS forecast to $4.15 - $4.20. CEO Richard M. Olson expressed optimism for future growth driven by productivity initiatives and strong positioning in attractive markets.
Haemonetics' Strategic Moves Poised To Boost Margins And Earnings, Says Analyst
Needham upgraded Haemonetics to Buy from Hold with a $112 price target, citing improved margin outlook.
Key factors for margin growth: reduced low-margin Plasma sales and expanded high-margin Interventional Technologies sales.
Haemonetics' Strategic Moves Poised To Boost Margins And Earnings, Says Analyst
- Analyst Upgrade: Needham & Co. analyst Mike Matson upgraded Haemonetics Corporation HAE from Hold to Buy with a price target of $112.
- Operating Margin Goal: Haemonetics aims for a "high-20%" FY26 operating margin, requiring a 600 basis point improvement from its FY24 margin of 21.1%.
- Factors Influencing Gross Margin: Analyst identified two key factors affecting gross margins - reduction in lower-margin Plasma sales to CSL and expansion of higher-margin Interventional Technologies sales.
- Financial Outlook: Matson estimates EPS of $4.60 for FY25 and $5.53 for FY26, expecting the company to meet its 27%+ operating margin target by then.
- Investment Opportunities: Investors can consider exposure to Haemonetics stock through Neuberger Berman Small-Mid Cap ETF NBSM and SPDR S&P Health Care Equipment XHE.
Toro Lowers Full-Year Outlook As Residential Sales Slump, Costs Weigh on Margins
Sales Performance: The Toro Company reported a 2% decrease in second-quarter fiscal 2025 sales to $1.32 billion, missing expectations, with significant declines in the residential segment and adjusted EPS slightly beating consensus.
FY25 Outlook: The company has lowered its FY25 adjusted EPS guidance and net sales growth outlook, while emphasizing strategic steps to navigate macroeconomic challenges, as reflected in a decline of TTC shares by 1.8%.
ITT Q1 Preliminary Results: Flat Revenue, Eyes $1 Billion In Orders, $500 Million In New Buybacks & More
Company Performance and Outlook: ITT Inc. shares fell premarket as the company reported preliminary first-quarter results, projecting $1.0 billion in orders and over $900 million in revenue, with adjusted EPS expected between $1.43 to $1.45. Revenue growth is anticipated from pumps aftermarket and connectors, despite weak aerospace demand.
Share Repurchase and New Product Launch: ITT plans to repurchase up to an additional $500 million in shares under its existing buyback plan and recently launched VIDAR, a smart motor aimed at reducing energy use and CO2 emissions, marking its entry into the industrial motor market.
Toro's Q1 Sales Miss Expectations, Weighed Down by Material Costs and Promotions
Quarterly Performance: The Toro Company reported a 1% decrease in first-quarter fiscal 2025 sales to $995 million, missing expectations, with residential segment sales down 8% while professional segment sales increased by 1.6%. Adjusted EPS rose 2% year-over-year to $0.65, surpassing estimates.
Future Outlook: Toro expects net sales growth of 0%-1% and adjusted EPS between $4.25 and $4.40 for FY25, amid uncertainties in the macro environment. The company has achieved $64 million in cost savings and aims for $100 million by fiscal 2027, planning to reinvest some savings for innovation and growth.
Why Is Outdoor Equipment Products Provider Toro Stock Plunging Today?
Third-Quarter Performance: The Toro Company reported a 6.9% year-over-year sales increase to $1.156 billion, which fell short of expectations, with adjusted EPS of $1.18 also missing consensus estimates. The company noted increased caution among homeowners and dealers affecting shipments.
FY24 Outlook and Future Initiatives: Toro revised its FY24 net sales growth expectation to about 1% and adjusted EPS forecast to $4.15 - $4.20. CEO Richard M. Olson expressed optimism for future growth driven by productivity initiatives and strong positioning in attractive markets.
Haemonetics' Strategic Moves Poised To Boost Margins And Earnings, Says Analyst
Needham upgraded Haemonetics to Buy from Hold with a $112 price target, citing improved margin outlook.
Key factors for margin growth: reduced low-margin Plasma sales and expanded high-margin Interventional Technologies sales.
Haemonetics' Strategic Moves Poised To Boost Margins And Earnings, Says Analyst
- Analyst Upgrade: Needham & Co. analyst Mike Matson upgraded Haemonetics Corporation HAE from Hold to Buy with a price target of $112.
- Operating Margin Goal: Haemonetics aims for a "high-20%" FY26 operating margin, requiring a 600 basis point improvement from its FY24 margin of 21.1%.
- Factors Influencing Gross Margin: Analyst identified two key factors affecting gross margins - reduction in lower-margin Plasma sales to CSL and expansion of higher-margin Interventional Technologies sales.
- Financial Outlook: Matson estimates EPS of $4.60 for FY25 and $5.53 for FY26, expecting the company to meet its 27%+ operating margin target by then.
- Investment Opportunities: Investors can consider exposure to Haemonetics stock through Neuberger Berman Small-Mid Cap ETF NBSM and SPDR S&P Health Care Equipment XHE.
